351 related articles for article (PubMed ID: 10308905)
1. Pharmacy U.R. cuts costs, drug use.
Mosier RL
Hosp Peer Rev; 1979 May; 4(5):70-2. PubMed ID: 10308905
[No Abstract] [Full Text] [Related]
2. Cost savings achieved through cephalosporin use review and restriction.
Dzierba SH; Reilly RT; Caselnova DA
Am J Hosp Pharm; 1986 Sep; 43(9):2194-7. PubMed ID: 3766571
[TBL] [Abstract][Full Text] [Related]
3. Methods of controlling cephalosporin use in Canadian hospitals.
Godin JP; Sketris IS; Merrett RA; Marrie TJ
Can J Hosp Pharm; 1988 Apr; 41(2):73-4, 83-4, 96. PubMed ID: 10287052
[TBL] [Abstract][Full Text] [Related]
4. An approach to regulating cephalosporin use and costs.
Ryan JL; Francese J
Hosp Formul; 1980 Sep; 15(9):674-6. PubMed ID: 10248357
[No Abstract] [Full Text] [Related]
5. Financial impact of formulary revision of second-generation cephalosporins.
Andrews JD; Hafting S
Can J Hosp Pharm; 1988 Jun; 41(3):125-7. PubMed ID: 10288499
[TBL] [Abstract][Full Text] [Related]
6. How pharmaceutical controls worked in one Ontario hospital.
McLean WM; Tierney MG
Can J Hosp Pharm; 1994 Aug; 47(4):176-9. PubMed ID: 10136951
[No Abstract] [Full Text] [Related]
7. Pharmaceuticals in Australia: priorities in a teaching hospital.
Kearney BJ
Physician Exec; 1993; 19(5):63-7. PubMed ID: 10130953
[TBL] [Abstract][Full Text] [Related]
8. Analysis of factors influencing antibiotic usage in hospitals.
Sabath LD; Notto DA
Prog Clin Biol Res; 1979; 35():65-74. PubMed ID: 538037
[No Abstract] [Full Text] [Related]
9. Impact of parenteral cephalosporin regulation on pharmacy costs.
Ryan JL; Francese J
Hosp Formul; 1983 May; 18(5):510-2. PubMed ID: 10260198
[No Abstract] [Full Text] [Related]
10. Automatic interchange policy for first-generation i.v. cephalosporins.
Suzuki NT
Am J Hosp Pharm; 1987 Mar; 44(3):505. PubMed ID: 3565404
[No Abstract] [Full Text] [Related]
11. A penny saved.
Warren RW
Tex Hosp; 1979 Mar; 34(10):27. PubMed ID: 10240711
[No Abstract] [Full Text] [Related]
12. Filling and refilling practices with diazepam and methyldopa.
Scrivens JJ; Weber C; Sather M; Geck W
Hosp Formul; 1979 Sep; 14(9):830-1,834-6,838. PubMed ID: 10243909
[No Abstract] [Full Text] [Related]
13. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
Quercia RA; Chow MS; Jay GT; Quintiliani R
Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
[TBL] [Abstract][Full Text] [Related]
14. Computers justification: a pharmacy case study.
Jacobs JB
Tex Hosp; 1983 Nov; 39(6):32-3. PubMed ID: 10310406
[No Abstract] [Full Text] [Related]
15. Computerized billing as a tool for drug utilization.
Pelissier NA
Hosp Pharm; 1979 Dec; 14(12):711, 714-7. PubMed ID: 10309083
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic surveillance: the results of a clinical pharmacy intervention program.
Capers CC; Bess DT; Branam AC; Falbe WJ; Mrochek SA; Haymond JD; Stahl AA
Hosp Pharm; 1993 Mar; 28(3):206-10, 212. PubMed ID: 10124947
[TBL] [Abstract][Full Text] [Related]
17. Cephalosporin-use restrictions in teaching hospitals.
McCloskey WW; Johnson PN; Jeffrey LP
Am J Hosp Pharm; 1984 Nov; 41(11):2359-62. PubMed ID: 6507437
[TBL] [Abstract][Full Text] [Related]
18. Drug cost containment in the hospital.
Smith WE
Hosp Formul; 1978 Sep; 13(9):695-8. PubMed ID: 10238490
[No Abstract] [Full Text] [Related]
19. Benefits of clinical pharmacy services in a community hospital.
Williams LE
Hosp Pharm; 1993 Aug; 28(8):759-63, 766-7. PubMed ID: 10127576
[TBL] [Abstract][Full Text] [Related]
20. Cost benefit of pharmacy audit and nonrestrictive antibiotic policy.
Ware GJ; Ford DJ
N Z Med J; 1993 Apr; 106(954):160. PubMed ID: 8479665
[No Abstract] [Full Text] [Related]
[Next] [New Search]
